SCHEMBL1269604

SCHEMBL1269604

Cc1nc(NS(=O)(=O)c2ccc(C(F)(F)F)cc2Cl)ncc1Sc1ccc2ccccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.49
CYP3A4 P08684 1/20 0.49
LMNA P02545 2/20 0.44
POLB P06746 1/20 0.44
HTT P42858 1/20 0.44
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
PIK3C3 Q8NEB9 1/20 0.42
MCL1 Q07820 4/20 0.41
SLC40A1 Q9NP59 2/20 0.40
ALDH1A1 P00352 1/20 0.40
GLA P06280 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
SGK1 O00141 1/20 0.39
ALPL P05186 1/20 0.38
GAA P10253 1/20 0.38
CDK1 P06493 1/20 0.37
CCNB1 P14635 1/20 0.37
CCNA2 P20248 1/20 0.37
CCND1 P24385 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1269522 0.88 SLC40A1 (0.48) PPARGCYP3A4SLC40A1ALPL
SCHEMBL1268542 0.83 ALDH1A1 (0.42) PPARGCYP3A4LMNAPOLBHTT
SCHEMBL1269704 0.82 GAA (0.46) LMNAHTTPIK3C3ALDH1A1GAA
SCHEMBL12931031 0.82 IDH1 (0.41) PPARGCYP3A4POLBSLC40A1ALPL
SCHEMBL2032023 0.80 PPARG (0.52) PPARGCYP3A4LMNACNR1CNR2
SCHEMBL2034935 0.77 PPARG (0.56) PPARGCYP3A4LMNACNR1CNR2
SCHEMBL1268646 0.76 SLC40A1 (0.45) PPARGCYP3A4SLC40A1ALPL
SCHEMBL1268512 0.76 PPARG (0.45) PPARGCYP3A4SLC40A1ALPL
SCHEMBL1269561 0.76 CCR4 (0.51) PPARGCYP3A4HTTSLC40A1ALPL
SCHEMBL12931665 0.74 LMNA (0.45) LMNAALDH1A1GAAKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 US disclosed
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 US disclosed
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 US disclosed
EP-1786782-B1 BISARYL-SULFONAMIDES AMGEN INC (US) 2010-03-31 EP disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 US disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 US disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 US disclosed
US-20060084802-A1 Bisaryl-sulfonamides AMGEN INC. 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221584-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG PPARG 3/4885CYP3A4 615/4885LMNA 2576/4885
US-20060084802-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG PPARG 3/4885CYP3A4 615/4885LMNA 2576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.